Crescent Biopharma, Inc. Common Stock

Crescent Biopharma (Nasdaq: CBIO), a clinical-stage oncology biotechnology company, announced the pricing of an underwritten public offering of 8.1 million ordinary shares at $14.50 per share and 525,897 pre-funded warrants at $14.499 per warrant, expected to raise approximately $125 million in gross proceeds. The offering is expected to close on...

The combined company will operate as “Gyre Therapeutics, Inc.” with its common stock traded on Nasdaq under trading symbol “GYRE” effective Tuesday, October 31, 2023

Gainers Abri SPAC I, Inc. (NASDAQ: ASPA) shares climbed 127.1% to $28.39. Abri's stockholders approved its proposed business combination with DLQ. Nuvve Holding Corp. (NASDAQ: NVVE) shares climbed 88% to $0.2789 after falling 10% on Tuesday. Nuvve recently announced pricing of a $1 million underwritten public offering of roughly 7 million share...

Gainers INVO Bioscience, Inc. (NASDAQ: INVO) jumped 375% to $2.57 as the company agreed to acquire NAYA Biosciences in an all-stock transaction. LumiraDx Limited (NASDAQ: LMDX) shares climbed 187.4% to $0.25 after the company reported a strategic collaboration with AstraZeneca and Everton in the Community to set up England’s first community-ba...

Gainers LumiraDx Limited (NASDAQ: LMDX) shares surged 151.7% to $0.2190 in pre-market trading after the company reported a strategic collaboration with AstraZeneca and Everton in the Community to set up England’s first community-based heart and lung screening hub. Akumin Inc. (NASDAQ: AKU) shares rose 56.6% to $0.2285 in pre-market trading aft...